Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Hansa Medical in connection with a directed share issue
Mandate

Vinge advises Hansa Medical in connection with a directed share issue

November 15, 2018 Capital Markets and Public M&A

The board of directors of Hansa Medical has resolved on a directed new issue of shares, whereby Hansa Medical will raise proceeds of approximately SEK 453 / USD 50 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Cowen, RBC Capital Markets and Skandinaviska Enskilda Banken.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications.

Vinge’s team has consisted of Dain Hård Nevonen, Erik Sjöman, Joakim Hagberg and Edin Agic. 
 

Related

Vinge has advised SBB and Sveafastigheter in connection with an exchange offer

 Vinge has advised Samhällsbyggnadsbolaget i Norden AB (SBB) and Sveafastigheter AB in connection with an exchange offer directed to investors in SBB’s outstanding bonds, whereby investors exchanged senior and hybrid bonds in SBB for new senior bonds issued in Sveafastigheter AB. The existing bonds were partly issued under SBB’s EMTN programme, partly on a standalone basis. Following the transaction, the investors have been slotted in under Swedish bond terms on a standalone basis.
July 09, 2024

Vinge advises Polar Structure AB in connection with its issuance of EUR 81 million senior secured notes through a majority owned subsidiary

 Vinge advises Polar Structure AB, a leading developer and owner of infrastructure, in connection with its issuance of EUR 81 million senior secured notes through a majority owned subsidiary. The proceeds will be used to finance the construction of a railway outside Boden, which will connect the existing iron ore line (Sw. Malmbanan) with H2 Green Steel’s new facility for large-scale production of green steel at Boden Industrial Park.
July 04, 2024

Vinge advises Bergs Timber AB (publ) and Bitus A

 Vinge advises Bergs Timber AB (publ) and Bitus AB in connection with the divestment of the Fågelfors pellets business to J. Rettenmeier & Söhne. The Fågelfors pellets factory is based in Fågelfors in Högsby. The acquisition is subject to customary regulatory approvals.
July 03, 2024